BioVectra Continues Aggressive Investment Plan With New Facility Acquisition and Fermentation Capacity Expansions

BioVectra Inc. continues to invest in its core competencies, fermentation and downstream processing capacity. Planned investments to the end of 2015 are in the range of $30 million, including the following highlights:

1. Acquisition of the former Sepracor API production facility located in Nova Scotia, Canada
2. Installation of an additional 30,000-L fermentation capacity
3. Installation of $5 million in improved downstream purification equipment to support existing fermentation capacity with specialized capabilities in potent intermediate and API purification processing
4. Investment in new pre-clinical fermentation and potent chemistry suites.

BioVectra has demonstrated its ability to deliver high-quality, custom manufacturing services and
specialized MPEG reagents to many of the top pharmaceutical companies operating around the globe. By
employing flexibility, transparency, and responsiveness in its service delivery to clients, it has formed and
utilized several unique models in supply and co-development partnership.

“We will continue to be a strong partner of choice for companies developing specialized therapeutics, and
offer a range of capabilities, including handling complex molecules, potent API’s, MPEG reagents,
conjugation chemistries, and small and large molecules produced from microbial fermentation from early
development stage on through to commercial supply” stated Heather Delage, Vice President of Business
and Strategic Development for BioVectra.